Transgene (Euronext Paris: TNG) requested the suspension of its stock on Euronext Paris on November 26, 2025, pending the release of a capital increase announcement. Trading will resume on November 27, 2025, following the disclosure of the capital increase results. The company focuses on developing immunotherapy products for cancer treatment, with clinical-stage therapies like TG4050 showing promising results in head and neck cancer patients. Additional viral vector-based therapies are also in development, showcasing Transgene’s commitment to innovative precision medicine. For more information, visit www.transgene.com.

Read more at GlobeNewswire: Transgene annonce la reprise de la cotation de ses actions